Loading...

Home
ETF
HRTX

HRTX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

HRTX News

Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE

Jan 10 2026Yahoo Finance

Heron Therapeutics Reports $154.9M Net Revenue for 2025

Jan 09 2026Globenewswire

Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - December 18, 2025

Dec 18 2025NASDAQ.COM

Heron Launches APONVIE for Rapid Prevention of Postoperative Nausea and Vomiting

Dec 04 2025Globenewswire

Heron Therapeutics Reveals APONVIE® (aprepitant) Injectable Emulsion Added to Updated Fifth Consensus Guidelines for Postoperative Nausea and Vomiting (PONV) Management

Dec 04 2025Yahoo Finance

Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - November 13, 2025

Nov 13 2025NASDAQ.COM

Heron Therapeutics Inc. Reports Larger Q3 Loss, Falls Short of Expectations

Nov 04 2025NASDAQ.COM

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

Aug 15 2025Newsfilter

Wednesday 8/13 Insider Buying Report: WBD, HRTX

Aug 13 2025NASDAQ.COM

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Aug 08 2025NASDAQ.COM

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

Aug 08 2025Newsfilter

Heron Therapeutics announces capital restructuring to support growth

Aug 08 2025SeekingAlpha

Heron Therapeutics GAAP EPS of -$0.02 misses by $0.01, revenue of $37.2M misses by $0.88M

Aug 08 2025SeekingAlpha

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

Aug 08 2025PRnewswire

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

Aug 08 2025PRnewswire

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

Jul 29 2025Newsfilter